autologous anti-HER2 CAR-CD28 T cells

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human epidermal growth factor 2 (HER2; ErbB2; HER-2) and coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 CAR-CD28 T cells target and bind to HER2-expressing tumor cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.